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SUMMARY:  The childhood brain tumour medulloblastoma includes four subtypes with very different 
prognoses.  Here, we show that paracrine signals driven by mutant Beta-Catenin in WNT-medulloblastoma – 
an essentially curable form of the disease – induce an aberrant fenestrated vasculature that permits the 
accumulation of high levels of intra-tumoural chemotherapy and a robust therapeutic response.  In contrast, 
SHH-medulloblastoma – a less curable disease subtype – contains an intact blood brain barrier, rendering 
this tumour impermeable and resistant to chemotherapy.  The medulloblastoma-endothelial cell paracrine 
axis can be manipulated in vivo, altering chemotherapy permeability and clinical response.  Thus, 
medulloblastoma genotype dictates tumour vessel phenotype, explaining in part the disparate prognoses 
among medulloblastoma subtypes and suggesting an approach to enhance the chemoresponsiveness of other 
brain tumours. 
 
SIGNIFICANCE:  Some cancers respond remarkably well to treatment.  Better understanding of this 
treatment sensitivity could identify more effective therapies for less curable tumours.  With this in mind, 
studies have focused on tumour cell intrinsic determinants of treatment response but the role of the 
microenvironment is less well understood.  We show that the balance of agonistic and antagonistic WNT-
signals from medulloblastoma cells in vivo, dictates whether tumour vessels form a functional blood brain 
barrier and therefore the degree to which medulloblastomas are exposed and respond to systemic 
chemotherapy.  Because this tumour-endothelium WNT-signalling axis can be manipulated, 
pharmacological interventions might be used to disrupt the blood brain barrier in less curable brain tumours, 
increasing their exposure and response to chemotherapy. 
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INTRODUCTION 
Techniques that characterise the sequence and expression of the genome have transformed our understanding 
of cancer.  These approaches are especially powerful for studying tumours that display an important clinical 
phenotype, such as a dramatic response to treatment (Chang et al., 2014; Marx, 2015).  Large-scale 
sequencing efforts have shown that TSC1 mutations in bladder cancer, and rearrangements of ALK in non-
small cell lung cancer, predict response to the mTOR inhibitor everloimus and tyrosine kinase inhibitor 
crizotinib, respectively (Iyer et al., 2012; Soda et al., 2007; Solomon et al., 2014).  Gene expression profiling 
has also identified subtypes of human cancer that are unusually sensitive to conventional therapies, although 
the biological reason for this sensitivity is often unknown (Reis-Filho and Pusztai, 2011; Roberts and 
Mullighan, 2015).   
 
Medulloblastoma, the most common malignant childhood brain tumour, includes four subtypes that are 
readily identified by genomic profiling (Jones et al., 2012; Northcott et al., 2012b; Pugh et al., 2012; 
Robinson et al., 2012). SHH-, Group 3- and Group 4-medulloblastomas arise from cerebellar progenitor 
cells and are fatal in 40% to 70% of cases (Gajjar et al., 2006; Kawauchi et al., 2012; Northcott et al., 2012a; 
Northcott et al., 2011; Oliver et al., 2005; Uziel et al., 2005; Yang et al., 2008).  These tumours contain 
mutations that activate the SHH pathway (SHH-medulloblastoma) or focal amplifications of MYC or MYCN 
(Group-3 and Group-4).  In stark contrast, WNT-medulloblastomas arise from the lower rhombic lip,  are 
curable even when metastatic,  and frequently contain activating mutations in CTNNB1 (Ellison et al., 2005; 
Gajjar et al., 2006; Gibson et al., 2010; Northcott et al., 2012a; Northcott et al., 2011).  It is not known if the 
different origins, driver mutations or some other factor accounts for the different prognoses of 
medulloblastoma subtypes.  Therefore, we sought to understand the biological basis of WNT-
medulloblastoma treatment sensitivity since this might improve the treatment of other brain tumours. 
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RESULTS 
WNT-medulloblastomas contain aberrant vascular networks  
As a first step to understand the exquisite treatment sensitivity of WNT-medulloblastoma, we looked for 
features that were unique to these tumours relative to the three other medulloblastoma subtypes.  During a 
comprehensive review of two independent patient cohorts recruited from the Children’s Hospital Boston 
(n=43) and Packard Children’s Hospital Stanford (n=45) we found that that 90% (n=9/10) of primary human 
(h)WNT-medulloblastomas were frankly haemorrhagic at surgery compared with <12.5% of the other three 
subtypes (hSHH-medulloblastoma [12.5%; n=3/24], hGroup 3-medulloblastoma [9%, n=2/22], and hGroup 
4-medulloblastoma [0%, n=32]; p<0.0001, Chi-squared; Figure 1A).  Remarkably, 60% (n=28/47) of a 
genetic mouse model of hWNT-medulloblastoma (hereon, mWnt-medulloblasoma) that develops in Blbp-
Cre
+/-
 ; Ctnnb1
+/lox(ex3)
 ; Tp53
+
/
flx
 mice also contained macroscopic haemorrhages, relative to only 6.3% 
(n=2/32) of mShh-medulloblastomas in Ptch
+/-
; Cdkn2c
-/-
 mice, and 0% (n=0/16) of Myc
+
; Tp53
-/-
 mGroup 
3-medulloblastomas (Gibson et al., 2010; Kawauchi et al., 2012; Uziel et al., 2005; p<0.0001, Chi-squared; 
Figure 1A and 1B).  No mouse model of Group-4 medulloblastoma is currently available. 
 
Because central nervous system (CNS) haemorrhaging can result from aberrant angiogenesis and blood brain 
barrier (BBB) specification (Vallon et al., 2014), we studied these vascular features in formalin fixed 
paraffin embedded (FFPE) sections of the different human medulloblastoma subtypes.  The mean vascular 
density of hWNT-medulloblastomas (8.1%±0.69SE% PECAM1 expression) was approximately four times 
greater than that of hSHH- (1.9%±0.05SE), hGroup 3- (2.7%±0.30SE) or hGroup 4-medulloblastomas 
(1.7%±0.42SE; p<0.05, Mann-Whitney; Figures 1C, D and S1).  Immunohistochemical analysis of 
endothelial cells in these same tumour samples, as well as normal human kidney and brain, showed that 
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hSHH-, hGroup 3- and hGroup 4-medulloblastoma contain SLC2A1
+
/Plasmalemma Vesicle Associated 
Protein (PLVAP)
-
 vessels typical of the normal BBB (Daneman et al., 2010a; Stenman et al., 2008).  
Conversely, hWNT-medulloblastomas contained an aberrant, non-CNS-like, SLC2A1
-
/PLVAP
+
 vascular 
endothelium (p<0.001, Mann-Whitney; Figure 1E and F).   
 
To more rigorously quantify the vascular differences among medulloblastoma subtypes, and to determine if 
these are recapitulated by genetic mouse models of the disease, we used confocal microscopy to measure 
vessel density (Pecam1 immunoflourescence), tortuosity (number of vessel branch points) and endothelial 
BBB immunophenotype throughout 50μm frozen sections of eight variants of genetic mouse models of 
medulloblastoma.  We similarly studied frozen sections of orthotopic xenografts of hWNT- and hSHH-
medulloblastoma (hereon, xWNT- and xSHH-medulloblastoma).   In keeping with our observations of 
primary human tumours, all three genetic variants of mWnt-medulloblastoma and xWNT-medulloblastomas 
contained dense, markedly branched vascular networks that displayed a Slc2a1
-
/Plvap
+
, non-BBB like 
immunophenotype (Figures 2A-D and S2).  This pattern was significantly different from that seen in the five 
genetic mouse models of mShh- and mGroup 3-medulloblastoma, as well as xSHH-medulloblastoma that 
each contained a relatively sparse, non-tortuous and Slc2a1
+
/Plvap
-
 BBB-like vasculature.  Importantly, six 
of the eight genetic mouse models of medulloblastoma that we studied are generated by Cre-dependent or 
lentiviral-mediated mutation of neural progenitors and therefore contain wild-type endothelial cells.  Thus, 
although direct perturbation of signaling in endothelial cells can alter BBB development and integrity 
(Alvarez et al., 2011), vascular phenotype in mouse medulloblastoma appears to be driven by tumour 
genotype rather than germline mutations inherited by endothelial cells.  This is also likely to be true of the 
great majority of human tumours that rarely arise in the context of germline mutations in WNT, SHH or 
other signaling pathways. 
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Medulloblastoma subtypes have different developmental origins (Gibson et al., 2010; Goodrich et al., 1997).  
Therefore, differences in tumour vessel phenotype could reflect normal regional variations in the developing 
brain vasculature.  To test this, we studied vascular networks in the developing hindbrains of embryonic day 
(E) 14.5, E17.5, postnatal day (P) 6 and P60 mice.  All normal brain regions – including the embryonic 
dorsal brainstem from which WNT-medulloblastomas arise (Gibson et al., 2010) – contained non-tortuous, 
Slc2a1
+
/Plvap
-
 vascular networks similar to those observed in SHH-, Group 3- and Group 4-
medulloblastomas (Figure 2E-H).  Thus, the aberrant vasculature of WNT-medulloblastomas is not a 
developmental legacy.  Remarkably, hyperplasia of the embryonic dorsal brainstem that is the precursor 
lesion of mWnt-medulloblastoma already contained aberrant Slc2a1
-
/Plvap
+
 blood vessels similar to those 
found in daughter tumours, while vessels in precursor lesions of mShh-medulloblastomas were 
morphologically and immunophenotypically normal (Figure 3).  Thus, WNT-medulloblastomas possess an 
aberrant, non-CNS vasculature that is different from the other three disease subtypes and is likely to be 
driven by tumour genotype.  
 
WNT-medulloblastomas lack a functional BBB 
To further characterize the vascular differences among medulloblastoma subtypes we compared the 
transcriptomes of endothelial cells isolated from normal mouse brains (n=8), mWnt- (n=8 tumours) and 
mShh-medulloblastomas (n=8 tumours).  The transcriptomes of mShh-medulloblastoma endothelial cells 
were very similar to those of normal brain endothelium (Bolton et al., 1998; Daneman et al., 2010a; Schinkel 
et al., 1996).  In marked contrast, mWnt-medulloblastoma endothelium down-regulated genes normally 
enriched in CNS endothelium, including Cldn5 and Slc2a1 that are regulated by Wnt signaling in endothelial 
cells, and upregulated genes expressed in the peripheral endothelium (Figure 4A,B; Zhou et al., 2014).  Co-
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immunofluorescence and/or quantitative reverse transcriptase polymerase chain reaction analyses of a panel 
of BBB and pan-endothelial markers confirmed these observations (Figure 4 C,D). We also observed down-
regulation of several Notch pathway genes in mWnt-medulloblastoma endothelium (Figure 4A). Interaction 
of Wnt and Notch signaling pathways are known to regulate vascular branching in the developing CNS 
(Corada et al., 2010), and may partially explain the highly branched phenotype we see in mWnt-
medulloblastomas.  
 
Because WNT-medulloblastoma endothelial cells expressed a peripheral vessel-like transcriptome, including 
PLVAP that is a key component of vascular fenestrations, we looked to see if the vessels in these tumours 
contained pores (Firth, 2002).  As predicted, transmission and 3D scanning electron microscopy readily 
identified 60-80nm fenestrated pores connecting the luminal and abluminal compartments of mWnt-
medulloblastoma endothelium (Figure 4E).  Endothelial tight junctions were also disrupted in mWnt-
medulloblastomas, with areas of decreased junctional density and detachment between cells.  Conversely, no 
fenestrations or disrupted tight junctions were observed in mShh-medulloblastoma endothelium (Figure 4F).  
Vessel coverage by pericytes also plays an important role in BBB maintenance (Armulik et al., 2010; 
Daneman et al., 2010b; Reis et al., 2012).  Pericyte coverage was modestly but significantly decreased in 
mWnt- relative to mShh-medulloblastomas which may be due in part to decreased expression of PDGF in 
mWnt-medulloblastoma endothelium (p<0.05, Mann-Whitney; Figure 4A, G).  
 
To test directly if BBB integrity is lost in WNT-medulloblastoma, we measured tumour vessel permeability 
in vivo.  The vasculature of normal brain and mShh-medulloblastoma was impervious to systemically 
delivered 70kDa TMR-Dextran, but TMR-Dextran leaked readily into the tissue fluid of mWnt-
medulloblastomas (Figure 5A-C; p<0.0001, Mann Whitney). Endogenous immunoglobulin-G also leaked 
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into the tissue fluid of mWnt- but not mShh-medulloblastomas (Figure 5B).  Differences in the extravasation 
of TMR-Dextran and immunoglobulins were not due to differences in vascular perfusion between tumour 
subtypes, since intra-vascular levels of systemically delivered Lectin-FITC were similar in mWnt- and 
mShh-medulloblastomas (Figure 5 B,D).  Notably, the hyperplastic precursor lesions of mWnt-, but not 
mShh-medulloblastoma, were also aberrantly porous (Figure 3).  Thus, in contrast to the other 
medulloblastoma subtypes, WNT-medulloblastomas specify an aberrant, non-CNS vasculature that lacks a 
functional BBB. 
 
WNT-medulloblastoma paracrine signals block endothelial WNT-signaling 
During CNS development Wnt ligands secreted by neural progenitors induce angiogenesis and 
barriergenesis in neighboring endothelial cells, establishing a paracrine loop that maintains the BBB 
throughout life (Daneman et al., 2009; Stenman et al., 2008; Ye et al., 2009; Yuen et al., 2014). hWNT- and 
mWnt-medulloblastomas produce large amounts of WNT antagonists, (e.g. Wnt Inhibitor Factor 1 [WIF1], 
Dickkopf 1 [DKK1]; Figure 6A,B) presumably as part of a negative feedback loop to silence constitutive 
mutant CTNNB1 activity (Northcott et al., 2011; Thompson et al., 2006).  Therefore, we reasoned that these 
inhibitors may block WNT signaling and BBB specification in neighboring endothelial cells. As a first step 
to test this we looked in tumours for evidence of nuclear Lef1 expression that reports active WNT signaling 
(Logan and Nusse, 2004).  As expected, >96%±1.2SEM of hWNT, xWNT and mWnt tumour cells in which 
WNT signaling is constitutively activate, contained Lef1
+
 nuclei; but ≤23%±2.5SEM of endothelial cell 
nuclei in these tumours were Lef1
+
 (Figure 6C,D). The opposite pattern was observed in hSHH, xSHH and 
mShh-medulloblastomas that contained <0.9%±1.7SEM Lef1
+
 tumour nuclei but ≥82.5%±2.9SEM Lef1+ 
endothelial cell nuclei (all comparisons p<0.0005, Mann-Whitney; Figure 6C,D).  Thus, endothelial WNT 
signaling is markedly reduced in WNT-, relative to SHH-medulloblastoma. 
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To demonstrate more directly that WNT-medulloblastoma cells secrete factors capable of silencing WNT 
signaling in adjacent cells, we measured the capacity of tumour cell conditioned media (CM) to suppress 
enhanced Green Fluorescence Protein (eGFP) expression by a TCF-eGFP reporter cell line (Biechele et al., 
2009).  mWnt-medulloblastoma cell CM abolished Wnt3a-mediated signaling in this system almost 
completely, decreasing reporter activity from 89.0%±2.17SEM to 5.6%±1.31SEM (p<0.0005 Mann-
Whitney; Figure 6E).  In contrast, mShh-medulloblastoma CM reduced reporter activity only modestly, from 
89.0%±2.17SEM to 72.7%±4.8SEM (p<0.05).  Changes in phospho-CTNNB1
S37/T41
 expression in reporter 
cells mirrored the impact of CM on eGFP reporter activity (Figure 6F).  WIF1 is one of the most abundant 
Wnt antagonists secreted by WNT-medulloblastomas (Figure 6A,B).  Blockade of Wif1 production by 
mWnt-medulloblastoma cells significantly impaired the ability of their CM to inhibit Wnt-signaling (Figure 
6E and G; p<0.005 Mann-Whitney).  Thus, paracrine signals from mWnt-medulloblastoma cells that include 
Wif1 likely silence Wnt-signaling in neighboring endothelial cells. 
 
Disruption of WNT-medulloblastoma paracrine signaling restores the BBB 
To test if paracrine signaling between WNT-medulloblastoma and endothelial cells specifies the BBB in 
vivo, we modified the balance of this paracrine loop in tumours.  To overcome the suppressor effect of Wnt 
inhibitors secreted by mWnt-medulloblastomas, we transduced these cells with a Wnt7a-encoding lentivirus 
(mWnt
Wnt7a
).  Conversely, we generated a Wnt-inhibitory paracrine signal from mShh-medulloblastoma cells 
by transducing these tumour cells with a Wif1-Dkk1-endcoding lentivirus (mShh
Wif1-Dkk1
).  mWnt
Wnt7a
, 
mShh
Wif1-Dkk1
, or empty vector control cells (mWnt
control 
or mShh
control
) were then implanted separately into 
the hindbrains of CD1-nude mice.  Expression of exogenous Wnt7a or Wif1-Dkk1 did not significantly 
impact medulloblastoma formation or vessel density and tortuosity, although Wnt7a expressing tumour 
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vessels displayed a more tubular morphology (Figures 7A-C and S3).  However, secretion of Wnt7a had a 
profound impact on the vasculature in mWnt-medulloblastomas: restoring almost completely canonical 
endothelial Wnt signaling (Lef1
+
 nuclei increase, 21%+22% to 85%+5%; p<0.005, Mann-Whitney; Figure 
7C,D); reverting the vessel immunophenotype from Slc2a1
-
/Plvap
+ 
to Slc2a1
+
/Plvap
-
 (both markers 
p<0.0005, Mann-Whitney; Figure 7 C and E); and generating a functional, TMR-Dextran impervious, BBB 
(p<0.005, Mann-Whitney; Figure 7C and F).  Conversely, secretion of Wif1 and Dkk1 by mShh
Wif1-Dkk1
-
medulloblastomas, partially but significantly suppressed endothelial Wnt-signaling (Lef1
+
 nuclei decrease, 
98%+2% to 67%+1%; p<0.005, Mann-Whitney; Figure 7C,D) and reverted about a third of vessels from 
Slc2a1
+
/Plvap
- 
to Slc2a1
-
/Plvap
+
 (both markers p<0.005, Mann-Whitney; Figure 7C,E).  These relatively 
modest effects detectably, but non-significantly, increased vessel porosity in mShh
Wif1-Dkk1
-
medulloblastomas (Figure 7C,F).  
  
To further demonstrate the role of tumour-endothelial cell signaling in BBB specification, we generated 
tumours with admixed populations of mWnt
control
 and mWnt
Wnt7a
 cells.  mWnt
Wnt7a
-medulloblastoma cell 
regions in hybrid tumours contained Slc2a1
+
/Plvap
-
, non-porous, blood vessels, while adjacent mWnt
control
-
medulloblastoma regions contained aberrant Slc2a1
-
/Plvap
+
, porous vessels (Figure 7G,H). Thus, tumour-
endothelial paracrine signaling dictates vessel phenotype in medulloblastoma and can be manipulated by 
altering the balance of Wnt agonists and antagonists. 
 
BBB integrity dictates medulloblastoma treatment sensitivity 
The BBB impedes the access of chemotherapies to brain tumours (Muldoon et al., 2007). Therefore, we 
reasoned that the lack of a BBB in WNT-medulloblastomas might increase their exposure to systematic 
chemotherapy and contribute to the excellent prognosis of these tumours.  To test this, we investigated the 
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penetration of systemic chemotherapy into mWnt
control
 and mShh
control
-medulloblastomas in vivo and the 
associated therapeutic response.  First, we confirmed that mWnt
control
- and mShh
control –medulloblastoma cells 
are equally sensitive in vitro to vincristine, methotrexate and cisplatin that form the backbone of 
medulloblastoma chemotherapy (Figure 8A).  Thus, mWnt-medulloblastomas are not intrinsically more 
sensitive to chemotherapy.  Among these drugs, vincristine has proved especially controversial as a 
treatment of medulloblastoma since it has limited BBB penetration but causes significant peripheral 
neurotoxicity (Boyle et al., 2004; Verstappen et al., 2005).  Therefore, we selected vincristine for further 
study.  Tumour bearing mice were treated with three doses of 1.6mg/kg/dose/week vincristine (equivalent to 
the clinical dose of 3.3mg/m
2
).  Despite the equivalent in vitro sensitivity of mWnt
control
 and mShh
control
-
medulloblastomas to vincristine, this treatment doubled the median survival time of mice harboring 
mWnt
control–medulloblastomas but had no impact on the survival of mice with mShhcontrol-medulloblastoma 
(p<0.005, log rank; Figure 8A,B).  This difference in treatment response did not correlate with plasma 
pharmacokinetics that were equivalent between mice harboring mWnt
control
- and mShh
control
-
medulloblastomas; rather, the tissue fluid of mWnt
control
-medulloblastomas contained between 30 and 100-
fold more vincristine than did mShh
control
-medulloblastomas, corresponding to a >300 fold increase in 
tumour distribution coefficient (KPT) of vincristine in mWnt
control
- relative to mShh
control
-medulloblastomas 
(p<0.05 for all time points, Mann-Whitney; Figure 8C).  Thus, the aberrant vasculature formed in WNT-
medulloblastomas by tumour-endothelial cell signaling, renders these tumours porous to systemic 
chemotherapies that do not penetrate SHH-medulloblastoma, likely contributing at least in part to the 
excellent prognosis of WNT-medulloblastoma.  Finally, as an additional test of this hypothesis we looked to 
see if the secretion of Wnt7a that restores a functional BBB in mWnt-medulloblastoma without effecting 
tumour growth, blocks vincristine efficacy.  Although Wnt
Wnt7a
- and Wnt
control
-medulloblastoma cells were 
equally sensitive to vincristine in vitro, the restoration of BBB function in Wnt
Wnt7a
-medulloblastomas 
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blocked access of vincristine to these tumours and rendered them completely resistant to vincristine therapy 
in vivo (Figures 8C,D).   
 
DISCUSSION 
Some cancers respond remarkably well to treatment.  Better understanding of this treatment sensitivity could 
identify more effective therapies for less curable tumours (Chang et al., 2014; Marx, 2015).  With this in 
mind, many studies have focused on tumour cell-intrinsic determinants of treatment sensitivity, often 
seeking mutations that dictate response to small molecule inhibitors of signaling proteins (Iyer et al., 2012; 
Kool et al., 2014).  Much less is known about how the tumour microenvironment influences treatment 
response; although cancer-associated fibroblasts, immune cells and the vasculature have each been 
implicated (Junttila and de Sauvage, 2013).  For example, colony stimulating factor-1 (CSF-1)-dependent 
tumour associated macrophages promote the invasion of breast cancer and glioma cells, suggesting CSF-1 as 
a possible therapeutic target (Pyonteck et al., 2013), and tumour cell-intrinsic WNT signaling has been 
reported to exclude T-cells from melanoma, promoting resistance to anti-PD-L1/anti-CTLA-4 monoclonal 
antibody therapy (Spranger et al., 2015).  Here, we identify a signaling paradox in which mutant CTNNB1 
that drives constitutive, oncogenic WNT signaling in medulloblastoma (Gibson et al., 2010), simultaneously 
silences WNT signaling in surrounding endothelial cells through the production of secreted inhibitors.  As a 
consequence, WNT-medulloblastomas form a highly aberrant and haemorrhagic vasculature that lacks a 
BBB, rendering these tumours vulnerable to systemic chemotherapy and potentially explaining why these 
tumours are curable even when metastatic.    
 
Our identification of differences in the BBB among the various medulloblastoma subtypes has important 
consequences for the use of existing surgical, radiation and chemotherapies as well as the development of 
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new therapies.  Complete resection of medulloblastoma has long been regarded as an important component 
of curative therapy, but this can result in cerebellar mutism; a devastating syndrome of loss of speech, 
hypotonia and ataxia (Avula et al., 2015).  Therefore, a pre-surgical diagnosis of WNT-medulloblastoma 
could allow surgeons to test whether complete resection of these highly curable tumours is required.  WNT-
medulloblastomas can be differentiated from the other medulloblastoma subtypes using pre-operative 
magnetic resonance imaging (MRI) because WNT-medulloblastomas arise exclusively from the brainstem 
(Gibson et al., 2010).  However, diagnoses of medulloblastoma subtype that are based on anatomical 
location alone are inaccurate in one third of patients (Perreault et al., 2014).  Our data suggest that the unique 
vascular phenotype of WNT-medulloblastoma, including the presence of intratumoural bleeding or tumour 
penetration by BBB-impermeable contrast agents on MRI, could improve the accuracy with which these 
tumours are diagnosed.  The relative rarity of WNT-medulloblastoma and the variability in the approaches 
used to image these tumours means that only limited amounts of heterogeneous clinical data are available for 
retrospective review.  Furthermore, current imaging approaches employ smaller conventional agents e.g., 
gadolinium (~550Da) that are known to penetrate even a minimally compromised BBB (Perreault et al., 
2014).  Therefore, we are embarking on a prospective imaging clinical trial using large contrast agents to test 
if WNT-medulloblastomas are associated with a unique, BBB-penetrant image phenotype.  
 
Radiation is another source of severe long term side effects for survivors of medulloblastoma.  Therefore, the 
excellent prognosis of WNT-medulloblastoma has raised the question of whether these tumours can be cured 
with minimal or no radiation (Gajjar and Robinson, 2014).  While an attractive proposition, ideally the 
eradication of highly effective radiation therapy would be balanced by the introduction of a new, less toxic 
curative therapy.  But options for these alternative treatments have been limited by the assumption that all 
medulloblastomas contain an intact BBB that limits drug penetration (Muldoon et al., 2007).  Our 
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demonstration that WNT-medulloblastomas lack a BBB suggests a much larger cadre of drugs could be used 
to treat this tumour; including large molecules such as naked or conjugated therapeutic immunoglobulins.  
Small molecule inhibitors with limited penetration of an intact BBB should also be considered.  For 
example, the histone deacetylase inhibitor panobinostat is particularly attractive since disruption of 
chromatin modelling is thought play an important role in WNT-medulloblastoma (Northcott et al., 2012a).   
 
In addition to drugs, since the endothelium regulates the traffic of immune cells into tissues, the porosity of 
WNT-medulloblastoma suggests immunotherapeutic approaches might prove useful to treat these tumours.  
Indeed, increased vessel patency and porosity have been reported to enhance both immune cell infiltration of 
tumours and the efficacy of tumour vaccines (Junttila and de Sauvage, 2013).  Using these pre-clinical 
model systems will be important to develop novel combinations of chemotherapeutic regimens that may cure 
WNT-medulloblastomas without the need for radiation. That said, it is important to note that since the 
tumour vasculature dictates the local oxygen tension, the aberrant vessels in WNT-medulloblastoma might 
impact the efficacy of radiation therapy (Jain, 2014).  Therefore, testing if the vascular phenotype of WNT-
medulloblastoma enhances the radiosensitivity and curability of these tumours will also be important.   
 
Our demonstration that the BBB is intact in SHH-medulloblastoma (and likely the other disease subgroups), 
underscores the principle that BBB-impermeable drugs are likely to be much less effective treatments of 
these tumours.  Vincristine is a relatively large drug (~825Da), with a high plasma binding affinity, that 
serves as a substrate for multi drug-resistance transporters; these characteristics markedly impede its ability 
to cross an intact BBB (Boyle et al., 2004; Wang et al., 2010).  Despite these unfavorable pharmacological 
properties and a toxicity profile that includes severe peripheral neurotoxicity, vincristine is still used to treat 
all subtypes of medulloblastoma (Verstappen et al., 2005).  We show that mShh-medulloblastomas are 
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impermeable and unresponsive to vincristine in vivo, strongly suggesting this drug should not be used to 
treat this tumour type; a notion supported by studies that have limited the accumulative dose of this drug 
without impacting survival (Gajjar et al., 2006).   
 
Directly disrupting the BBB in non-WNT-medulloblastomas and other less curable brain tumours might 
allow the use of otherwise BBB-impermeable drugs to treat these tumours;  but, agents that disrupt the BBB 
have proven difficult to develop (Parrish et al., 2015).  In the normal brain, the BBB is maintained by 
agonistic neuronal-endothelial cell Wnt signaling (Daneman et al., 2009; Stenman et al., 2008; Ye et al., 
2009; Yuen et al., 2014; Zhou et al., 2014).  We show that an aberrant, antagonistic medulloblastoma-
endothelial cell Wnt-signal disrupts the BBB in Wnt-medulloblastomas.  Importantly, we also provide proof-
of-principle that this paracrine axis can be manipulated in vivo. Enhancing Wnt signaling in mWnt-
medulloblastoma endothelium restored a functional BBB in these tumours, while secretion of Wnt-inhibitors 
by mShh-medulloblastomas partially disrupted the BBB.  Thus, pharmacological blockade of WNT-
signaling in the endothelium of non-WNT-medulloblastoma and other brain tumours might enhance their 
exposure to systemically delivered therapeutics. Future studies are required to determine the ability of small 
molecule inhibitors of WNT (Kahn, 2014) to disrupt the BBB and increase chemotherapy penetration in 
non-WNT-medulloblastomas.  
 
EXPERIMENTAL PROCEDURES 
Human tumours 
All human data and medulloblastomas were obtained with appropriate informed consent and Boston, 
Packard and St. Jude Children’s Research Hospitals individual Institutional Review Board’s approvals.  
Medulloblastomas were subtyped using Affymetrix gene expression profiling as previously described 
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(Northcott et al., 2011). Surgical reports of patients were reviewed for various clinical features including 
intra-tumoural haemorrhaging by two independent observers who were blind to medulloblastoma subtype.  
 
Mouse models of medulloblastoma 
All animal experiments were performed under St. Jude Children’s Research Hospital approved IACUC 
protocols and performed according to the relevant regulatory standards. mWnt-medulloblastoma ([Blbp-
Cre
+/-
 ; Ctnnb1
+/lox(ex3)
 ; Tp53
+
/
flx
 ; Pik3ca
loxE545K/loxE545K
], [Blbp-Cre
+/-
 , Ctnnb1
+/lox(ex3)
 ; Tp53
+
/
flx
], and [Blbp-
Cre
+/-
 , Ctnnb1
+/lox(ex3)
 ; Pik3ca
loxE545K/loxE545K
]), mShh-medulloblastoma ([Ptch
+/-
; Cdkn2c
-/-
 , Ptch
+/-
; Tp53
-/-
], 
[Math1-CreERT2 ; Ptch1
flx/flx
], and [hGFAP-Cre
+/- 
; SmoM2
flx/flx
]) and mGroup 3-medullobastoma models 
were generated exactly as described (Gibson et al., 2010; Kawauchi et al., 2012; Uziel et al., 2005).  Each of 
these tumours have been shown to have robust activation of the corresponding Wnt or Shh signal pathway.  
Mice of the appropriate genotype were subjected to clinical surveillance for evidence of tumour formation as 
described (Gibson et al., 2010).  
 
cDNAs encoding Wnt7A, Wif1, Dkk1 or empty control were subcloned into the pCDH-EF1-MCS-T2A-
copGFP lentiviral plasmid (Systems Bioscience). 19mer shRNA sequences targeting Wif1: 
GCTCATAGGATTTGAAGAA, GGGCAGAGATGCATAAATT were cloned into the H1-RFP lentivirus.  
Orthotopic transplants of tumour cells transduced with control or test lentiviruses were generated exactly as 
described previously (Mohankumar et al., 2015).  Briefly, 1.5x10
6
 tumour cells transduced with a YFP-
luciferase lentivirus were resuspended in 5 μl Matrigel an injected via a 3mm borehole into the cerebellum 
anaesthetised CD-1 nude mice.  Mice were monitored for tumour development using bioluminescence 
(Mohankumar et al., 2015). Medulloblastoma xenografts were similarly generated.  One sample each of 
freshly resected hWNT- and hSHH-medulloblastoma was collected under informed consent with approval of 
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the St. Jude Children’s Research Hospital Institutional Review Board.  1.5x106 human tumour cells 
transduced with a YFP-luciferase lentivirus were then resuspended in 5 μl Matrigel an injected via a 3mm 
borehole into the cerebellum anaesthetised CD-1 nude mice. 
 
Blood brain barrier permeability and vessel perfusion assays 
100 μl of a 10 mg/ml 70kDa Dextran-TMR solution (#D1818, Life Technologies) was injected via the tail 
vein into mice harboring the indicated medulloblastoma mouse allograft. Two hours later animals were 
perfused with phosphate buffered saline (PBS) and 4% paraformaldehyde. Their brains were then removed 
and post-fixed overnight.  Vessel perfusion studies were similarly conducted although mice were injected 
with 1.0 mg/ml Lectin-FITC (Sigma-Aldrich), and brains harvested 10 minutes post injection. 
 
Histology 
Tissue microarrays of human tumours were stained immunohistochemically using standard techniques and 
the following primary antibodies: PECAM1 (1:50; Cell Marque #131M-94), LEF1 (1:250; Cell Signaling 
#C12A5), SLC2A1 (1:500; Millipore #07-1401) and PLVAP (1:100; Sigma #HPA002279). Dye Light 
secondary antibodies (488 and 647 conjugates, Jackson ImmunoResearch) were used for fluorescent 
visualization, along with Hoechst dye (Life Technologies).  
 
Immunofluorescence of 50 μm sections of fresh frozen medulloblastoma mouse allografts or xenografts 
were performed using standard techniques. Briefly, sections were blocked in 10% normal donkey serum for 
1 hour and then incubated overnight with one or more of the following primary antibodies: PECAM1 (1:200; 
BD Biosciences #550274), LEF1 (1:500; Cell Signaling #C12A5), PLVAP (1:200; BD Biosciences 
#550563), SLC2A1 (1:1000; Millipore #07-1401), Wif1 (1:500; Abcam #ab33281), Wnt7A (1:500; Abcam 
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#ab100792), PDGFR-β (1:250; eBioscience #14- 1402), Desmin (1:500; Millipore #AB3623), P-
Glycoprotein (1:50; Millipore #517310).  Sections were then incubated with corresponding secondary 
antibodies (Jackson ImmunoResearch, Dye Light 488, 594 and 647) and nuclei stained with Hoechst dye 
(Life Technologies). Sections were imaged using a Zeiss ImagerM2 with Apotome or Zeiss 510 LSM 
META confocal microscope and analyzed in Axiovision, ZEN, and Image J.  
 
For quantification of vessel density or branch points based on PECAM1 expression or SLC2A1/PLVAP 
expression, 0.894 μm x 0.670 μm images were collected across serial sections of tumours, and then 
processed in ImageJ to determine percent area of stain.  PECAM1/LEF1 quantification was performed in 
ZEN (Zeiss) on random tumor fields at 40 x (0.22 μm2 z- stacks).  PECAM1/Desmin quantification was 
performed on random fields at 20x (0.44 μm2 z-stack).  For quantification of TMR-Dextran leakage, entire 
tumor regions were imaged across serial sections at (0.894 μm x 0.670 μm).  GFP+ tumor regions were 
selected and TMR pixel intensity recorded for each selection. Human tissue microarray sample cores were 
imaged in their entirety, and then quantified for blood vessel co-localization of PLVAP/SLC2A1 staining in 
ZEN.  
 
For electron microscopy (EM) studies, mice harboring mWnt or mShh-medulloblastomas were deeply 
anaesthetised with Avertin (250 mg/kg) and then perfused with EM buffer (0.1M sodium cacodylate pH 7.4) 
and fixative (0.1M sodium cacodylate pH 7.4 + 2% Paraformaldehyde + 2.5% Gluteraldehyde). Brains were 
then and vibratome sectioned into 2% osmium tetroxide in 0.1M cacdylate buffer with 0.15% potassium 
ferrocyanide, dehydrated and then embedded in epoxy resin. Ultra-thin sections (80nm) were then cut and 
imaged using a Tecnai TF20 transmitting electron microscope.  For 3D scanning electron microscopy, 500 
nm thick sections were coated with iridium in a Denton Desk II sputter coater and imaged using a Helios 
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Nanolab 660 FIB-SEM Dualbeam system. 3D image stacks at 5x5x5nm resolution were processed and 
reconstructed using Amira 6.0 software. 
 
Endothelial cell studies 
Tumour and normal brain samples were digested in papain (Worthington, 5 units/ml) and filtered single cell 
suspensions incubated with mouse Eng-PE and Cdh5-PE antibodies (eBioscences #12-1051, 12- 1441). 
Cells were then incubated with anti-PE microbeads (Milyenitec) and then processed through two consecutive 
MS separation columns (Milyenitec). Total RNA was isolated from Eng/Cdh5-PE cell fractions and mRNA 
expression profiles generated using Affymetrix Mouse Gene 2.0ST microarrays exactly as described 
(Mohankumar et al., 2015).  RNA samples were analysed by reverse transcriptase polymerase chain reaction 
analysis using the following primers: GAPDH (AGGTCGGTGTGAACGGATTTG; 
TGTAGACCATGTAGTTGAGGTCA), Pecam1 (ACGCTGGTGCTCTATGCAAG 
TCAGTTGCTGCCCATTCATCA), Cdh5 (CCACTGCTTTGGGAGCCTT; 
GGCAGGTAGCATGTTGGGG), Eng (CCCTCTGCCCATTACCCTG; 
GTAAACGTCACCTCACCCCTT), Slc2a1 (CAGTTCGGCTATAACACTGGTG; 
GCCCCCGACAGAGAAGATG), Ocln (TTGAAAGTCCACCTCCTTACAGA;  
CCGGATAAAAAGAGTACGCTGG), Abcb1a (CAGCAGTCAGTGTGCTTACAA; 
ATGGCTCTTTTATCGGCCTCA), Plvap (GCTGGTACTACCTGCGCTATT; 
CCTGTGAGGCAGATAGTCCA). 
 
Cell Culture 
Primary cultures of mWnt- and mShh-medulloblastoma cells were generated and maintained in Neurobasal 
medium as described (Gibson et al., 2010).  293T cells transduced with a lentiviral Wnt-reporter construct 
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(Biechele et al., 2009) were treated with Wnt3a (R&D; 120ng/ml) in control or tumour conditioned media 
for 24 hours before quantifying the proportions of eGFP and mCherry expressing cells by fluorescence 
activated cell sorting. For western blot analysis, protein lysates were collected from the indicated cells and 
processed using standard techniques.  Blots were probed with the following primary antibodies: Wif1 
(Abcam, #ab33281), Wnt7a (Abcam, #ab100792) β-Actin (Cell Signaling, #4967), Ctnnb1 (Cell Signaling, 
#9587), phospho-Ctnnb1
S37/T41
 (Millipore, #05-665). Total protein levels were estimated by Coomassie blue 
staining of nitrocellulose membrane.  The proliferation of single cell suspensions of tumour cells cultured in 
neurobasal medium, in the presence or absence of the indicated drugs was recorded using CellTiter-Glo as 
described (Atkinson et al., 2011).   
 
In vivo vincristine efficacy and pharmacology studies 
For efficacy studies, vincristine was dissolved in 0.9% sodium chloride (0.16mg/ml) and administered via 
tail vein injection (1.6mg/kg) weekly starting at initiation of tumour growth based on bioluminescence. Mice 
were imaged for bioluminescence weekly, and monitored daily for neurological symptoms.  To define the 
vincristine disposition in CD-1 nude mice and to derive a pharmacokinetic limited sampling model (LSM), 
we performed a plasma pharmacokinetic (PK) study in non-tumour bearing CD-1 nude mice.  Mice (n=9) 
were dosed with 1.6mg/kg vincristine and blood samples collected using a population based study design. 
Each mouse was sampled three times at pre-determined time-points using retro-orbital eye bleeds except at 
the terminal time-point, where the sample was collected using cardiac puncture.  Plasma samples were 
analyzed using a validated LCMS-MS method and a 2-compartment model was fitted to the plasma 
concentration-time data using non-linear mixed effect modeling (NONMEM 7.3, ICON Development 
Solutions, Ellicott City, MD).  Two separate tumour disposition studies of vincristine were performed. When 
mice became symptomatic due to tumour burden, they were dosed with 1.6mg/kg vincristine and sacrificed 
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at LSM derived time-points (5 min, 30 min, and 2 hr) post-dose.  Plasma and tumour concentration-time data 
were analysed using a naïve-pooled analysis. A 2-compartment model consisting of a tumour compartment 
linked to a central compartment via CLIN (influx clearance) and CLOUT (efflux clearance) was fitted to 
plasma and tumour concentration-time data using a Bayesian method implemented in ADAPT 5 where PK 
parameters obtained from the initial plasma PK study were used as priors. The tumour to plasma partition 
co-efficient (KPT) was calculated as a ratio of area under the tumour concentration-time curve to the plasma 
concentration-time curve (AUCTumour/AUCPlasma).  
 
Accession numbers 
Mouse brain and medulloblastoma endothelial cell RNA microarray data are available from GEO 
(GSE73753).   
 
AUTHOR CONTRIBUTIONS 
Timothy Phoenix
 
conducted the great majority of the studies reported in the paper, including the histology, 
in vitro and in vivo mouse work.  Deanna Patmore, Nidal Boulos, Megan O. Jacus, Yogesh T. Patel and 
Clinton F. Stewart
 
completed the preclinical vincristine pharmacokinetic and therapeutic studies.  Scott Boop 
contributed to the histology studies of human and mouse medulloblastoma.  Liliana Goumnerova, Sebastien 
Perreault, Elizabeth Wadhwa, and Yoon-Jae Cho
 
conducted the analysis of tumour inra-operative 
haemorrhaging in patients treated with medulloblastoma.  Richard Gilbertson
 
conceived and supervised the 
entire research project.  All authors participated in the preparation of the manuscript. 
 
ACKNOWLEDGEMENTS 
22 
 
This work was supported by grants from the National Institutes of Health (R.J.G., P01CA96832 and 
P30CA021765), the American Lebanese Syrian Associated Charities and Cancer Research UK. We are 
grateful to the staff of the Hartwell Center for Bioinformatics and Biotechnology, the Cell and Tissue 
Imaging Shared Resource and the ARC at St Jude Children’s Research Hospital for technical assistance.  
 
 
REFERENCES 
 
Alvarez, J. I., Dodelet-Devillers, A., Kebir, H., Ifergan, I., Fabre, P. J., Terouz, S., Sabbagh, M., Wosik, K., 
Bourbonniere, L., Bernard, M., et al. (2011). The Hedgehog pathway promotes blood-brain barrier integrity 
and CNS immune quiescence. Science 334, 1727-1731. 
 
Armulik, A., Genove, G., Mae, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., 
Lindblom, P., Strittmatter, K., et al. (2010). Pericytes regulate the blood-brain barrier. Nature 468, 557-561. 
 
Atkinson, J. M., Shelat, A. A., Carcaboso, A. M., Kranenburg, T. A., Arnold, L. A., Boulos, N., Wright, K., 
Johnson, R. A., Poppleton, H., Mohankumar, K. M., et al. (2011). An integrated in vitro and in vivo high-
throughput screen identifies treatment leads for ependymoma. Cancer Cell 20, 384-399. 
 
Avula, S., Mallucci, C., Kumar, R., and Pizer, B. (2015). Posterior fossa syndrome following brain tumour 
resection: review of pathophysiology and a new hypothesis on its pathogenesis. Child's nervous system : 
ChNS : official journal of the International Society for Pediatric Neurosurgery 31, 1859-1867. 
 
Biechele, T. L., Adams, A. M., and Moon, R. T. (2009). Transcription-based reporters of Wnt/beta-catenin 
signaling. Cold Spring Harb Protoc 2009, pdb prot5223. 
 
Bolton, S. J., Anthony, D. C., and Perry, V. H. (1998). Loss of the tight junction proteins occludin and 
zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier 
breakdown in vivo. Neuroscience 86, 1245-1257. 
 
Boyle, F. M., Eller, S. L., and Grossman, S. A. (2004). Penetration of intra-arterially administered vincristine 
in experimental brain tumor. Neuro-oncology 6, 300-305. 
 
23 
 
Chang, D. K., Grimmond, S. M., Evans, T. R., and Biankin, A. V. (2014). Mining the genomes of 
exceptional responders. Nat Rev Cancer 14, 291-292. 
 
Corada, M., Nyqvist, D., Orsenigo, F., Caprini, A., Giampietro, C., Taketo, M. M., Iruela-Arispe, M. L., 
Adams, R. H., and Dejana, E. (2010). The Wnt/β-Catenin Pathway Modulates Vascular Remodeling and 
Specification by Upregulating Dll4/Notch Signaling. Developmental Cell 18, 938-949. 
 
Daneman, R., Agalliu, D., Zhou, L., Kuhnert, F., Kuo, C. J., and Barres, B. A. (2009). Wnt/beta-catenin 
signaling is required for CNS, but not non-CNS, angiogenesis. Proceedings of the National Academy of 
Sciences of the United States of America 106, 641-646. 
 
Daneman, R., Zhou, L., Agalliu, D., Cahoy, J. D., Kaushal, A., and Barres, B. A. (2010a). The mouse blood-
brain barrier transcriptome: a new resource for understanding the development and function of brain 
endothelial cells. PloS one 5, e13741. 
 
Daneman, R., Zhou, L., Kebede, A. A., and Barres, B. A. (2010b). Pericytes are required for blood-brain 
barrier integrity during embryogenesis. Nature 468, 562-566. 
 
Ellison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D., 
and Clifford, S. C. (2005). beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: 
the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23, 7951-7957. 
 
Firth, J. A. (2002). Endothelial barriers: from hypothetical pores to membrane proteins. J Anat 200, 541-548. 
 
Gajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L. E., Merchant, T. E., Woo, S., Wheeler, G., 
Ahern, V., Krasin, M. J., et al. (2006). Risk-adapted craniospinal radiotherapy followed by high-dose 
chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude 
Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7, 813-820. 
 
Gajjar, A. J., and Robinson, G. W. (2014). Medulloblastoma[mdash]translating discoveries from the bench 
to the bedside. Nat Rev Clin Oncol 11, 714-722. 
 
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., Kranenburg, T. A., Hogg, T., 
Poppleton, H., Martin, J., et al. (2010). Subtypes of medulloblastoma have distinct developmental origins. 
Nature 468, 1095-1099. 
 
Goodrich, L. V., Milenkovic, L., Higgins, K. M., and Scott, M. P. (1997). Altered neural cell fates and 
medulloblastoma in mouse patched mutants. Science 277, 1109-1113. 
 
24 
 
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., 
Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012). Genome sequencing identifies a basis for everolimus 
sensitivity. Science 338, 221. 
 
Jain, Rakesh K. (2014). Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating 
Hypoxia. Cancer Cell 26, 605-622. 
 
Jones, D. T. W., Jager, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, 
V., Stutz, A. M., et al. (2012). Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 
100-105. 
 
Junttila, M. R., and de Sauvage, F. J. (2013). Influence of tumour micro-environment heterogeneity on 
therapeutic response. Nature 501, 346-354. 
 
Kahn, M. (2014). Can we safely target the WNT pathway? Nat Rev Drug Discov 13, 513-532. 
 
Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelstein, D., Qu, C., Pounds, S., 
Ellison, David W., et al. (2012). A Mouse Model of the Most Aggressive Subgroup of Human 
Medulloblastoma. Cancer Cell 21, 168-180. 
 
Kool, M., Jones, D. T., Jager, N., Northcott, P. A., Pugh, T. J., Hovestadt, V., Piro, R. M., Esparza, L. A., 
Markant, S. L., Remke, M., et al. (2014). Genome sequencing of SHH medulloblastoma predicts genotype-
related response to smoothened inhibition. Cancer Cell 25, 393-405. 
 
Logan, C. Y., and Nusse, R. (2004). THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND 
DISEASE. Annual Review of Cell and Developmental Biology 20, 781-810. 
 
Marx, V. (2015). Cancer: A most exceptional response. Nature 520, 389-393. 
 
Mohankumar, K. M., Currle, D. S., White, E., Boulos, N., Dapper, J., Eden, C., Nimmervoll, B., 
Thiruvenkatam, R., Connelly, M., Kranenburg, T. A., et al. (2015). An in vivo screen identifies 
ependymoma oncogenes and tumor-suppressor genes. Nat Genet 47, 878-887. 
 
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., 
Senter, P. D., Peereboom, D. M., and Neuwelt, E. A. (2007). Chemotherapy delivery issues in central 
nervous system malignancy: a reality check. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 25, 2295-2305. 
 
25 
 
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., 
Korshunov, A., Lichter, P., Taylor, M. D., and Pfister, S. M. (2012a). Medulloblastomics: the end of the 
beginning. Nat Rev Cancer 12, 818-834. 
 
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. 
C., Hawkins, C. E., French, P., et al. (2011). Medulloblastoma Comprises Four Distinct Molecular Variants. 
Journal of Clinical Oncology 29, 1408-1414. 
 
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Sorana Morrissy, A., Zichner, T., Stutz, A. M., 
Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012b). Subgroup-specific structural variation across 
1,000 medulloblastoma genomes. Nature 488, 49-56. 
 
Oliver, T. G., Read, T. A., Kessler, J. D., Mehmeti, A., Wells, J. F., Huynh, T. T., Lin, S. M., and Wechsler-
Reya, R. J. (2005). Loss of patched and disruption of granule cell development in a pre-neoplastic stage of 
medulloblastoma. Development 132, 2425-2439. 
 
Parrish, K. E., Sarkaria, J. N., and Elmquist, W. F. (2015). Improving drug delivery to primary and 
metastatic brain tumors: strategies to overcome the blood-brain barrier. Clin Pharmacol Ther 97, 336-346. 
 
Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., 
Bouffet, E., Fisher, P. G., et al. (2014). MRI Surrogates for Molecular Subgroups of Medulloblastoma. 
American Journal of Neuroradiology 35, 1263-1269. 
 
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., 
Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012). Medulloblastoma exome sequencing 
uncovers subtype-specific somatic mutations. Nature 488, 106-110. 
 
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., 
Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013). CSF-1R inhibition alters macrophage polarization and 
blocks glioma progression. Nat Med 19, 1264-1272. 
 
Reis-Filho, J. S., and Pusztai, L. (2011). Gene expression profiling in breast cancer: classification, 
prognostication, and prediction. The Lancet 378, 1812-1823. 
 
Reis, M., Czupalla, C. J., Ziegler, N., Devraj, K., Zinke, J., Seidel, S., Heck, R., Thom, S., Macas, J., 
Bockamp, E., et al. (2012). Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes 
tumor blood vessels by inducing PDGF-B expression. The Journal of Experimental Medicine 209, 1611-
1627. 
 
26 
 
Roberts, K. G., and Mullighan, C. G. (2015). Genomics in acute lymphoblastic leukaemia: insights and 
treatment implications. Nat Rev Clin Oncol 12, 344-357. 
 
Robinson, G., Parker, M., Kranenburg, T. A., Lu, C., Chen, X., Ding, L., Phoenix, T. N., Hedlund, E., Wei, 
L., Zhu, X., et al. (2012). Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48. 
 
Schinkel, A. H., Wagenaar, E., Mol, C. A., and van Deemter, L. (1996). P-glycoprotein in the blood-brain 
barrier of mice influences the brain penetration and pharmacological activity of many drugs. The Journal of 
clinical investigation 97, 2517-2524. 
 
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-i., Watanabe, H., 
Kurashina, K., Hatanaka, H., et al. (2007). Identification of the transforming EML4-ALK fusion gene in 
non-small-cell lung cancer. Nature 448, 561-566. 
 
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., 
Paolini, J., Usari, T., et al. (2014). First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung 
Cancer. New England Journal of Medicine 371, 2167-2177. 
 
Spranger, S., Bao, R., and Gajewski, T. F. (2015). Melanoma-intrinsic [bgr]-catenin signalling prevents anti-
tumour immunity. Nature 523, 231-235. 
 
Stenman, J. M., Rajagopal, J., Carroll, T. J., Ishibashi, M., McMahon, J., and McMahon, A. P. (2008). 
Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 
322, 1247-1250. 
 
Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., 
Adesina, A., Ashley, D. M., Kellie, S. J., et al. (2006). Genomics identifies medulloblastoma subgroups that 
are enriched for specific genetic alterations. J Clin Oncol 24, 1924-1931. 
 
Uziel, T., Zindy, F., Xie, S., Lee, Y., Forget, A., Magdaleno, S., Rehg, J. E., Calabrese, C., Solecki, D., 
Eberhart, C. G., et al. (2005). The tumor suppressors Ink4c and p53 collaborate independently with Patched 
to suppress medulloblastoma formation. Genes Dev 19, 2656-2667. 
 
Vallon, M., Chang, J., Zhang, H., and Kuo, C. J. (2014). Developmental and pathological angiogenesis in the 
central nervous system. Cellular and molecular life sciences : CMLS 71, 3489-3506. 
 
Verstappen, C. C., Koeppen, S., Heimans, J. J., Huijgens, P. C., Scheulen, M. E., Strumberg, D., Kiburg, B., 
and Postma, T. J. (2005). Dose-related vincristine-induced peripheral neuropathy with unexpected off-
therapy worsening. Neurology 64, 1076-1077. 
27 
 
 
Wang, F., Zhou, F., Kruh, G. D., and Gallo, J. M. (2010). Influence of blood-brain barrier efflux pumps on 
the distribution of vincristine in brain and brain tumors. Neuro-oncology 12, 1043-1049. 
 
Yang, Z. J., Ellis, T., Markant, S. L., Read, T. A., Kessler, J. D., Bourboulas, M., Schuller, U., Machold, R., 
Fishell, G., Rowitch, D. H., et al. (2008). Medulloblastoma can be initiated by deletion of Patched in 
lineage-restricted progenitors or stem cells. Cancer cell 14, 135-145. 
 
Ye, X., Wang, Y., Cahill, H., Yu, M., Badea, T. C., Smallwood, P. M., Peachey, N. S., and Nathans, J. 
(2009). Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal 
vascularization. Cell 139, 285-298. 
 
Yuen, T. J., Silbereis, J. C., Griveau, A., Chang, S. M., Daneman, R., Fancy, S. P., Zahed, H., Maltepe, E., 
and Rowitch, D. H. (2014). Oligodendrocyte-encoded HIF function couples postnatal myelination and white 
matter angiogenesis. Cell 158, 383-396. 
 
Zhou, Y., Wang, Y., Tischfield, M., Williams, J., Smallwood, P. M., Rattner, A., Taketo, M. M., and 
Nathans, J. (2014). Canonical WNT signaling components in vascular development and barrier formation. 
The Journal of clinical investigation 124, 3825-3846. 
 
 
FIGURE LEGENDS. 
Figure 1. Human and mouse medulloblastoma vessel phenotype. A. Frequency of intra-operative 
haemorrhages detected in human and mouse medulloblastomas.  B. Gross preparations of mouse 
medulloblastomas demonstrating numerous haemorrhages (arrows) in mWnt-medulloblastoma. 
Photomicrographs (C) and quantification (D) of PECAM1 immunohistochemical staining of human 
medulloblastomas.  Co-immunofluorescence (E) and quantification (F) of SLC2A1 and PLVAP expression 
in human kidney, brain and medulloblastoma. *=p<0.05, ***=p<0.0005, Mann-Whitney. See also Figure S1. 
All graphs bar=mean +SE. 
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Figure 2. BBB immunophenotype in mouse medulloblastoma and developing hindbrain.  A. Confocal 
immunofluorescence of Pecam1 (top) and co-immunofluorescence of Slc2a1 and Plvap (bottom) in mWnt-, 
mShh, and mGroup 3-medulloblastomas. Quantification of tumour vessel density (B), tortuosity (C), and 
Slc2a1/Plvap expression (D) in eight variant models of mWnt-, mShh, and mGroup 3-medulloblastoma.  E. 
Co-immunofluorescence of Slc2a1 and Plvap in developing mouse hindbrain.  Quantification of vessel 
density (F), tortuosity (G), and Slc2a1/Plvap expression (H) in developing mouse cerebellum (CB), 
brainstem (BS) and choroid plexus (CP) relative to mWnt- and mShh-medulloblastomas (MB). *=p<0.05, 
**=p<0.005, ***=p<0.0005, Mann-Whitney. See also Figure S2. All graphs bar=mean +SE. 
 
Figure 3. BBB immunophenotype and porosity in early hyperplasic precursor lesions of mWnt- and 
mShh-medulloblastoma.  Top: Hoechst staining illustrating the anatomy and location of lesions in the 
developing hindbrain. Middle: co-immunofluorescence of Slc2a1 and Plvap in precursor lesions of mWnt- 
and mShh-medulloblastoma. Bottom: Pecam1 immunofluorescence and TMR-dextran autoflourescence 
demonstrating leakage of dextran into mWnt- but not mShh-medulloblastoma precursor lesions. 
 
Figure 4.  Molecular and ultrastructural phenotype of mWnt- and mShh-medulloblastoma 
endothelium.  A. Unsupervised hierarchical clustering of BBB endothelial specific gene expression in 
endothelial cells isolated from mWnt- and mShh-medulloblastoma and normal brain.  B. Gene Set 
Enrichment Analyses of BBB endothelium enriched (left) and peripheral endothelium enriched gene 
expression in mWnt-medulloblastoma endothelial cells reporting normalized enrichment score (NES) and 
the false discovery rate (FDR) Q value.  C. Reverse-transcription quantitative polymerase chain reaction 
analyses of endothelial specific gene expression in endothelial cells isolated from normal brain, mWnt- and 
mShh-medulloblastoma.  D. co-immunofluorescence of Pecam1 and Abcb1a or Ocln expression in mWnt- 
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and mShh-medulloblastoma endothelium. Electron microscopy (EM) of endothelium in mWnt- (E) and 
mShh-medulloblastoma (F).  In both E and top=3D scanning EM, bottom=transmission EM.  View is from 
the interior of the vessel, bright objects are mitochondria. Note regular fenestrations in mWnt-
medulloblastomas on 3D scanning EM.  Red arrows=pores, yellow arrows=vesicles.  G. Co-
immunofluorescence (top) and quantification (bottom) of Desmin and Pecam1 expression in mWnt- and 
mShh-medulloblastoma. *=p<0.05, **=p<0.005, ***=p<0.0005, Mann-Whitney. All graphs bar=mean +SE. 
 
Figure 5.  BBB function in mWnt- and mShh-medulloblastoma.  A. Autofluorescence of TMR-Dextran 
in ex vivo whole brain preparations of mice harbouring mWnt- or mShh-medulloblastoma. Dotted lines 
demarcate tumours.  B. confocal microscopy of Pecam1 immunofluorescence and lectin-FITC 
autoflourescence (top), gamma-immunoglobulin coimmunofluorescence (middle); and TMR-dextran 
autoflourescence; (bottom).  Quantification of TMR-dextran in tissue fluid (C) and lectin-FITC in vessels 
(D) in mWnt- and mShh-medulloblastomas. ***=p<0.0005, Mann-Whitney. 
 
Figure 6. WNT-medulloblastoma paracrine signals silence WNT signalling in neighbouring cells.  A. 
Heat map of mRNA expression of secreted WNT inhibitors by human and mouse medulloblastoma (source 
data Gibson et al., 2010).  B. Immunofluorescence of Wif1 expression in mouse mWnt- and mShh-
medulloblastoma. Co-immunofluorescence (C) and quantification (D) of Pecam1 and Lef1 expression in 
mouse mWnt- and mShh-medulloblastoma, arrows=nuclei.  E. Fluorescence activated cell sorting plots 
quantifying TCF-reporter activity (x-axis) in TCF-reporter transduced cells (y-axis).  Numbers in plots 
denote the %+SE of reporter transduced and activated cells.  F. Western blots of total and phosphorylated 
Ctnnb1 in reporter cells shown in (E).  G. Western blots of Wif1 in mWnt-medulloblastoma cells transduced 
with Wif1-shRNAs.  *=p<0.05, **=p<0.005, ***=p<0.0005, Mann-Whitney. All graphs bar=mean +SE. 
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Figure 7.  Medulloblastoma-endothelial paracrine signals can be manipulated in vivo.  Kaplan-Meyer 
survival curves of (A) mShh
Wif1+Dkk1
- or (B) or mWnt
Wnt7a
-medulloblastomas relative to controls.  C. 
Immunofluorescence studies of the indicated proteins and TMR-dextran leakage in mShh
Wif1+Dkk1
- and 
mWnt
Wnt7a
-medulloblastomas relative to controls.  Quantification of Lef1
+
 endothelial nuclei (D), 
Slc2a1/Plvap expression (E) and TMR-dextran leakage (F) leakage in mShh
Wif1+Dkk1
- and mWnt
Wnt7a
-
medulloblastomas relative to controls.  Slc2a1/Plvap expression (G) and TMR-dextran leakage (H) in 
admixed tumours of mWnt
Wnt7a
- and mWnt
control
-medulloblastoma cells. **=p<0.005, ***=p<0.0005, Mann-
Whitney. See also Figure S3. 
 
Figure 8.  BBB function dictates medulloblastoma exposure and response to vincristine in vivo.  A. 
Growth inhibition assays of mouse medulloblastoma cells following 72 hour exposure to the indicated drugs.  
B. Kaplan-Meyer survival curves of mShh
control 
and mWnt
control
-medulloblastomas to vincristine therapy. C. 
Vincristine area under the curve (AUC) plots for plasma (left), tumour tissue fluid (middle) and KPT (right) 
in mice harbouring the indicated medulloblastomas. D. Kaplan-Meyer survival curves of mWnt
control
- or 
mWnt
Wnt7a
- medulloblastomas treated with vincristine therapy. *=p<0.05, **=p<0.005, Mann-Whitney. All 
graphs bar=mean +SE  
 
 
 
 
 
 
